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This perspective describes the differences between these later studies and the original experiments.
We highlight the necessity for using standardized and informative assessment tools and processes
when determining the age of development of AD or AD symptoms, and also stress that this clinical
phenotype is best measured reliably in prospective studies during which subjects are monitored over
time. This is true when assessing potential biomarkers for age of onset and when assessing the ther-
apeutic potential of medicines that may delay the onset or progression of this disease.
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ably confirm or, in particular, refute a previous result is
challenging. The checkered history of whole-genome asso-
ciation studies of complex human phenotypes attests to the
veracity of this statement. Unrecognized selection bias can
confound the replication of experimental results. Within an
experiment, measurement of variation must be both accurate
and consistently reproducible to be useful. For comparison
across experiments, the same measurements should be
conducted with the same level of precision and reproducibil-
ity. This is true for both the definition and measurement of
the phenotype, and of the genetic locus or loci of interest.
Measurement of variation can be relatively straightfor-
ward—measuring someone’s height, for example—or very
complex. Alzheimer’s disease (AD) research is proving to
be a challenge in measurement and recognition of possibly
confounding heterogeneity. Here, we describe where some
of those challenges lie in the research of AD genetics, ad-




Open access under CC BY-NCand also describe one example of an experiment to validate
prospectively the contribution of a genetic locus to a
quantitative trait—in this case, age of onset (AOO) of AD.
We also address the pragmatic use of the translocase of the
outer mitochondrial membrane pore subunit (TOMM40)
rs10524523 (523) and apolipoprotein E (APOE) genotypes
for enrichment of a clinical trial.
Twenty years ago, APOE was identified as a significant
risk factor for development of late-onset AD. Subsequent
studies have confirmed the relationship between this locus
and AD, which is not challenging using today’s technologies
and considering the large effect size of this locus for disease
risk. The risk is highest for those who are homozygous for
the APOE ε4 allele, or about 2% of whites. In addition, the
only APOE genotype agreed by the field to be useful for
the prediction of AOO of late-onset AD is APOE ε4/4. The
mean age of AD onset in APOE ε4/4 whites is approximately
70 years. Indeed, it is difficult to find cognitively normal in-
dividuals with the APOE ε4/4 genotype who are older than
90 years of age. Arguably,APOE ε2/2 is also highly informa-
tive because the occurrence of AD in people with this geno-
type is rare or nonexistent. However, only w1% of whites
have an APOE ε2/2 genotype. Therefore, the two potentially-ND license. 
Fig. 2. Age at onset of cognitive impairment curves for TOMM40 523 ge-
notypes. Data were obtained from The Joseph and Kathleen Bryan Alz-
heimer’s Disease Research Center (Bryan ADRC), Memory, Health &
Aging cohort [3] (n5 508, 106 conversion events) and were monitored pro-
spectively at the Bryan ADRC at Duke University. Age at which cognitive
impairment occurred was stratified by TOMM40 genotype, and Kaplan-
Meier curves were constructed. L, long; VL, very long; S, short.
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an extensive body of clinical information and molecular
studies added weight to the genetic findings and led to accep-
tance by the AD research field that carriage of APOE ε4, in
APOE ε4/4 and APOE ε3/4 genotypes, is deleterious. Indi-
viduals with APOE ε3/3, the most common genotype, and
also APOE ε2/3, are assumed to be unaffected by whatever
APOE ε4 does to increase disease risk and decrease the
AOO of AD. These assumptions subsequently led to broad
comparisons of APOE ε4-positive and APOE ε4-negative
groups in many clinical and pharmacological studies.
The genomic region surrounding the APOE gene is char-
acterized by strong linkage disequilibrium—different alleles
at polymorphic loci in the region tend to be co-inherited faith-
fully from generation to generation. A number of other genes
are encoded within the APOE region, including TOMM40,
which codes for the protein that forms the channel subunit
of themultisubunit complex in the outer mitochondrial mem-
brane through which nuclear-encoded proteins enter mito-
chondria. The association between the 523 polymorphism
and age of AD onset was first reported by Roses and col-
leagues [1]. Fig. 1 illustrates the type of genetic data, based
on DNA sequencing of the polymorphic poly-T, that de-
scribes the 523 locus. The sequencing identified three cate-
gorical length alleles for 523, and a two-haplotype system
for APOE ε3–523. Attached to APOE ε3, and also to
APOE ε2, which is thought to have arisen later in human his-
tory, is either a short (S;19 T residues) form or a very long
(VL; .29 T residues) form of 523. In contrast, 98% of the
time, APOE ε4 is linked to, and thus inherited with, the
long (L; 19–29 T residues in length) 523 poly-T allele.
The publication by Roses and colleagues [1] demon-
strated the power of phylogenetic mapping for post-
genomewide association study analysis of regions of highFig. 1. Histograms of 523 poly-T lengths and allele frequencies linked to
specific APOE alleles. The data were obtained from Sanger sequencing of
23-Kb DNA that contained both the 523 poly-T variant and the APOE epsi-
lon single nucleotide polymorphisms, so linkage between the 523 andAPOE
alleles was unambiguous. The data were obtained from a white cohort of 83
patients with Alzheimer’s disease and 67 age-matched control subjects, and
included subjects with APOE ε3/3, ε3/4, and ε4/4 genotypes (no ε2 alleles;
details of the cohort are given in Li and colleagues [2]). The overlap region
for the long (L) and very long (VL) categories is shown in the gray area.linkage disequilibrium, showing that haplotypes composed
of the 523 S allele and APOE ε3 have a different inferred
evolutionary history than haplotypes containing APOE ε3
linked to 523 VL. That is, APOE ε3–523 S and APOE ε3–
523 VL haplotypes segregate to different clades on the phy-
logenetic tree constructed from DNA sequences of the
APOE–523 region for AD patients and control subjects.
Similarly, 523 L, which is almost always linked to APOE
ε4, occurs in distinct clades, and the tree structure suggests
that APOE ε4–523 L haplotype has an evolutionary history
that is more similar to APOE ε3–523 VL than to APOE
ε3–523 S haplotypes. The branch of the tree that contains
the APOE ε3–523 VL and APOE ε4–523 L haplotypes is en-
riched for AD patients, whereas the branch containing
APOE ε3–523 S is relatively enriched for the control sub-
jects from the study group analyzed. The coincidence of dis-
tinct APOE ε3 haplotypes with APOE ε4 haplotypes on the
tree suggested that these APOE ε3 haplotypes might also be
associated with higher disease risk. In fact, the relationship
is stronger with age of disease onset than with lifetime
risk. Thus, by using phylogenetic mapping, resolution of
the contribution of different alleles/haplotypes within this
highly correlated region was discerned. There is a very large
risk signal that is undeniably associated with the APOE ε4–
523 L haplotype, but age-dependent risk can also now be as-
signed to haplotypes containing APOE ε3.
Fig. 2 illustrates stratification of the age of cognitive im-
pairment by 523 genotype in which case status is determined
clinically during an ongoing prospective study conducted by
the Joseph and Kathleen Bryan Alzheimer’s Disease Re-
search Center using carefully applied, standardized, and val-
idated neuropsychological tests [4,5]. The six Kaplan-Meier
curves illustrated in Fig. 2 map a single APOE ε4/4 AOO dis-
tribution, two distinct distributions for APOE ε3/4, and three
distributions for haplotypes containing APOE ε3/3 or APOE
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sponding to APOE ε3/3, now distinguished by the 523 geno-
types—S/S, S/VL, and VL/VL—provide risk estimates for
w40% of whites. No curves are provided for APOE ε2/4
or APOE ε2/2 separately (which together account for only
3% of the white population) because of insufficient numbers
of disease onset events for APOE ε2 carriers. Thus, the 523
genetic locus, discovered by phylogenetic mapping, is more
informative for AOO distributions than the two categories
provided by APOE ε3/4 and APOE ε3/3 (523 L/L and
APOE ε4/4 genotypes are almost perfect surrogates). By us-
ing 523 genotypes to stratify age-dependent disease risk, risk
predictions can be made for.97% of the population sample.
Some recent experiments have not replicated the associ-
ation of TOMM40 523 with AOO of AD, most notably re-
ports from Jun and associates [6] and Cruchaga and
coworkers [7]. An editorial that accompanied the article by
Jun and associates [6] asserted, based on the conditional
analysis presented by Jun and associates [6], that there was
no independent genetic association between TOMM40
523, nor any other single nucleotide polymorphism in the
TOMM40–APOE genomic region other than the two single
nucleotide polymorphisms that define the APOE genotype,
with AD risk [8]. Guerreiro and Hardy [8] (page 1243) state
that “The golden rule to consider a gene as a true risk factor
for a determined disease has been the ability to replicate the
original association.” This is a true statement; however, there
are several aspects to consider when asking why the meta-
analysis by Jun and associates [6] and the study by Cruchaga
and coworkers [7], which Roses has previously commented
on in Alzforum [9], do not replicate the association between
523 and AOO of AD as reported by Roses and colleagues
[1]. Box 1 lists the requirements for replication of the find-
ings by Roses and colleagues [1].
A number of methodological aspects may account for
the differences observed between the survival (age of AD
onset) analyses conducted by Jun and associates [6] com-
pared with the data shown in Fig. 2. The article by Jun
and associates [6] presents the results of a meta-analysisBox 1: Outline of steps necessary to corroborate the association of
TOMM40 523 polymorphism and age of onset of Alzheimer’s disease
onset
 Accurate, standardized definition of clinical age of onset from
prospectively monitored clinical cohorts
 An analytically validated assay for accurate TOMM40-523 poly-
T sizing
 Differentiation of the poly-T overlap region so that L, VL, and S
alleles can be assigned accurately to each individual
 Age of onset distributions for each 523 genotype (ie, not grouping
three distinct 523 genotypes into a single APOE ε3/3 risk group
using a proportion of a population)
 Accurate means of accounting for the presence of one or more
APOE ε4 or APOE ε2 alleles in an individual genotype
 Determination of whether an individual’s S or VL alleles are
linked to an APOE ε2 or APOE ε3 allele to provide an accurate
prognostic haplotypeof 15 data sets comprised of 11,840 AD patients and
10,931 cognitively normal elderly control subjects assem-
bled by the Alzheimer’s Disease Genetic Consortium for
genomewide association study research. Of all the larger
data sets, only 1256 patients and 1605 control subjects
were genotyped for the TOMM40 poly-T marker. Of the
complex assemblage of studies that yielded cases for the
analyses by Jun and associates [6], only some were pro-
spective, where incident cases were captured during the
course of the study. Other studies were cross-sectional, or
had a cross-sectional component, and would have contrib-
uted patients with retrospectively reported AOO of AD in
which recall and survivor biases are likely to undermine
the accuracy of the AOO data. Only one of the three studies
that were genotyped for TOMM40 by Jun and associates [6]
and used in their survival analyses was strictly prospective.
The Adult Changes in Thought Study (ACT) began with
cognitively normal subjects and incident cases of AD
were captured during the course of the study. The other
two studies—Alzheimer’s Disease Neuroimaging Initiative
(ADNI) and the Aging Alzheimer’s Disease Centers (ADC)
studies—are composed of both prevalent and incident
cases. It is not clear whether the ADNI or ADC data that
were used by Jun and associates [6] and Cruchaga and co-
workers [7] were only the incident cases. If prevalent cases
were included in the AOO analyses, AOO would be re-
ported retrospectively, and recall and survivor biases and
variously defined clinical presentations would confound
the interpretation of the results. Moreover, even prospective
studies may introduce methodological challenges resulting
from the use of different instruments or clinical staging
when cross-study comparisons are made. Within-study rec-
onciliation may also be problematic when a large number
of sites are involved, as with ADNI, because there is in-
creased risk for variability in application of the assessment
instruments and thus in ascertaining AOO. Unfortunately,
neither the uniformity, or lack thereof, of definitions of
AD diagnosis nor an assessment of accuracy or within-
and cross-study consistency for ascertaining AOO are de-
tailed in the article. For example, among the three series
used in the survival analyses [6], either the subject samples
analyzed from each study are very different, or case diag-
nosis is very different because (i) the average AOO for
the ACT sample is 12 years older than for ADNI or
ADC; (ii) the AOO distribution for APOE ε4-plus subjects
in the ACT study is pushed to later ages than the APOE ε4-
minus distribution, and both occur at later ages than seen
for the ADC and ADNI cases; and (iii) APOE ε4-plus
and ε4-minus AOO distributions are very similar within
ADNI and ADC samples. The critical measure for a delay
of disease onset clinical trial is the age at which symptoms
appear. Introducing error by allowing variability in the def-
inition of the end point or the measurement of that end
point will ensure the failure of the study.
A second potential source of measurement bias in this re-
search is a result of the technical difficulty of measuring
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correctly to an allele category: S, L, or VL. To reproduce the
original association study it would have been necessary for
Jun and associates [6] to use the polymerase chain reaction
(PCR)-plus-sequencing poly-T assay performed by Poly-
morphic DNA Technologies, Inc (Alameda, CA, USA), in
the original experiments by Roses and colleagues [1], be-
cause different assays will have unique measurement biases.
Approximately 9500 assays of 523 length have now been
performed by Polymorphic DNATechnologies for research
purposes, with continuous quality assurance monitoring.
Substantial data now exist for the reproducibility and robust-
ness of Polymorphic’s assay. The assay performed by Poly-
morphic DNA Technologies is available for fee-for-service
use at very low cost. Although some major research institu-
tions are employing this vendor to genotype the 523 locus
and APOE, others have developed assays de novo. These
other tests are unlikely to have the analytical validation of
the Polymorphic DNATechnologies assay.
The Polymorphic DNA Technologies assay uses Sanger
sequencing, whereas Jun and associates [6] and Cruchaga
and coworkers [7] used gel filtration sizing of PCR products
of the locus. After extensive analyses, Polymorphic DNA
Technologies found that the sequencing-based assay had
a standard deviation of 61–2 T as a consequence of PCR
slippage. For the longer 523 alleles, L and VL, for which
the length distributions overlap, the PCR slippage may intro-
duce error in the call of the categorical allele designation (L
or VL). Fig. 1 illustrates that the boundaries of the peaks for
allele lengths for L and VL are immediately adjacent so dif-
ferent methodologies for determining poly-T length will po-
tentially result in calling different categorical 523 alleles.
Fig. 1 further illustrates that as an internal check of the
523 allele calls at these boundaries, one can use a subject’s
APOE genotype to distinguish between L and VL, since L
is (almost without exception) linked to APOE ε4 and VL
is (almost without exception) not linked to APOE ε4 in
whites. For example, if all poly-T lengths .30 T (ie, the
gray overlap in Fig. 1) were labeled VL regardless of
APOE genotype, these could be miscalls because some
may be L alleles. Using APOE genotypes informs accurate
calls for 523 allele lengths in this overlap region.
It is necessary to test whether allele calls are consistent
among studies to know that findings in different studies
are comparable. Unfortunately, although Jun and associates
[6] had the means to do so, they did not report whether the
results of their 523 poly-T assay were concordant with allele
calls made using the sequencing-based assay performed by
Polymorphic DNATechnologies. This would have been pos-
sible with the ADNI cohort because Zinfandel Pharmaceuti-
cals, Inc (Durham, NC), sponsored the 523 and APOE
genotype tests for a subset of the ADNI cohort, and the
data were transferred to ADNI researchers. Earlier, Roses
and colleagues were interested in providing 523 genotypes
to the ADNI database and in co-authoring with ADNI col-
laborators an analysis of AOO stratified by 523 genotype.The genotype data were provided to ADNI collaborators be-
fore the AOO data were accessed and reviewed with them.
When Roses and colleagues examined how the AOOs
were determined for the ADNI series, it became clear that
there was insufficient standardization across sites for deter-
mining AOO, nor was there any way to verify the AOO of
each case. The best estimate of year of onset of AD symp-
toms was recorded; however, this was not defined uniformly
as the date of initial symptoms, diagnosis of mild cognitive
impairment (MCI) by stated criteria, or diagnosis of AD by
a clinician using standard diagnostic criteria of AD or MCI.
Because of the uncertainty of the AOO data, Roses and col-
leagues determined that a clinically useful article or a true
replication of the original association study could not be pro-
duced, and they chose not to participate in publication of an
AOO analysis of this data set.
The accuracy of the Kaplan-Meier curves of AOO strati-
fied by 523 genotype reported by Jun and associates [6] and
also by Cruchaga and coworkers [7] can reasonably be ques-
tioned considering the ambiguity introduced by the nonstan-
dardized determination of AOO, in which at least some of
the determinations are retrospective, and the potential for
miscalling of the 523 alleles in the area of overlap. Consis-
tent 523 genotype calls and accurately recorded and stan-
dardized determination of age of AD onset (within a year
or two in prospective clinical follow-up) should be the min-
imum requirement for a replication study (Box 1).
The APOE and TOMM40 523 genotype combination is
informative of age-dependent risk of AD for the white pop-
ulation. The importance of the relationship between APOE
and TOMM40 523 is not the independent statistical associa-
tion with AOO for AD. Rather, the use of the 523 poly-T ge-
notype increases the proportion of the at-risk population for
which genetics may provide an estimate of age-dependent
risk, and also improves resolution of age-dependent risk
for individual subjects, to support clinical research and de-
velopment of much-needed therapies. Although the APOE
ε4/4 genotype alone is informative of age-dependent risk
of disease for 2% of the white population, APOE and 523 ge-
notype information, when combined, is informative of age-
dependent AD risk for .97% of whites.
Conducting clinical trial practically to test a therapy for
delayADonset requires ameans to identify those at increased
risk of developing disease within the expected duration of
a trial. Without a risk enrichment strategy, prevention trials
will likely be much larger in size and/or take longer to accrue
sufficient numbers of end point conversions to demonstrate
statistical differences between treated and untreated groups.
The APOE and TOMM40 523 genotype combination appears
to provide the means to do this. The genotype combination as
a predictor of age-dependent risk of cognitive decline will be
validated in a prospective study, using standardized clinical
assessments for identifying onset of MCI resulting from
AD [10], uniformly conducted by trained clinicians at defined
time intervals, and using a technically validated assay for call-
ing genotypes. If, as a result of this study, it is demonstrated
A.D. Roses et al. / Alzheimer’s & Dementia 9 (2013) 132–136136that the age of AD onset can be delayed by a therapeutic, then
the statistical significance of TOMM40 relative to that of
APOE becomes a relatively trivial discussion.References
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